135 related articles for article (PubMed ID: 27008812)
21. Sustained release of naltrexone from poly(n-isopropylacrylamide) microgels.
Kjøniksen AL; Calejo MT; Zhu K; Cardoso AM; de Lima MC; Jurado AS; Nyström B; Sande SA
J Pharm Sci; 2014 Jan; 103(1):227-34. PubMed ID: 24218151
[TBL] [Abstract][Full Text] [Related]
22. Controlled drug release from the aggregation-disaggregation behavior of pH-responsive microgels.
Gao Y; Ahiabu A; Serpe MJ
ACS Appl Mater Interfaces; 2014 Aug; 6(16):13749-56. PubMed ID: 25118818
[TBL] [Abstract][Full Text] [Related]
23. Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation.
Jiang Y; Wang F; Xu H; Liu H; Meng Q; Liu W
Int J Pharm; 2014 Nov; 475(1-2):475-84. PubMed ID: 25219858
[TBL] [Abstract][Full Text] [Related]
24. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies.
Vitorino C; Almeida A; Sousa J; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC; Pais A
Eur J Pharm Biopharm; 2014 Feb; 86(2):133-44. PubMed ID: 24333401
[TBL] [Abstract][Full Text] [Related]
25. Second-generation long-acting injectable antipsychotic agents: an overview.
Drug Ther Bull; 2012 Sep; 50(9):102-5. PubMed ID: 22966099
[TBL] [Abstract][Full Text] [Related]
26. Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.
Sharma G; Italia JL; Sonaje K; Tikoo K; Ravi Kumar MN
J Control Release; 2007 Mar; 118(1):27-37. PubMed ID: 17258836
[TBL] [Abstract][Full Text] [Related]
27. Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.
Kozumplik O; Uzun S; Jakovljević M
Psychiatr Danub; 2009 Mar; 21(1):72-4. PubMed ID: 19270625
[TBL] [Abstract][Full Text] [Related]
28. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
Graffino M; Montemagni C; Mingrone C; Rocca P
Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
[TBL] [Abstract][Full Text] [Related]
29. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine.
Aggarwal G; Dhawan S; Harikumar SL
Pharm Dev Technol; 2013; 18(4):916-25. PubMed ID: 21913873
[TBL] [Abstract][Full Text] [Related]
30. Study of an injectable in situ forming gel for sustained-release of Ivermectin in vitro and in vivo.
Geng Z; Luo X; Zhang Z; Li H; Tian J; Yu Z
Int J Biol Macromol; 2016 Apr; 85():271-6. PubMed ID: 26708436
[TBL] [Abstract][Full Text] [Related]
31. Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy.
Khan UA; Parveen U; Hasan N; Ahmed MZ; Saad S; Ahmad FJ; Jain GK
Drug Des Devel Ther; 2020; 14():2237-2247. PubMed ID: 32606594
[TBL] [Abstract][Full Text] [Related]
32. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine.
Nahata T; Saini TR
J Microencapsul; 2008 Sep; 25(6):426-33. PubMed ID: 18608793
[TBL] [Abstract][Full Text] [Related]
33. Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats.
Dimer FA; Pigatto MC; Boque CA; Pase CS; Roversi K; Pohlmann AR; Burger ME; Rates MK; Dalla Costa T; Guterres SS
J Biomed Nanotechnol; 2015 Aug; 11(8):1482-93. PubMed ID: 26295148
[TBL] [Abstract][Full Text] [Related]
34. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo evaluation of an in situ forming gel system for sustained delivery of Florfenicol.
Yu ZG; Geng ZX; Liu TF; Jiang F
J Vet Pharmacol Ther; 2015 Jun; 38(3):271-7. PubMed ID: 25287575
[TBL] [Abstract][Full Text] [Related]
39. Development of Recombinant Human Growth Hormone (rhGH) sustained-release microspheres by a low temperature aqueous phase/aqueous phase emulsion method.
Kang J; Wu F; Cai Y; Xu M; He M; Yuan W
Eur J Pharm Sci; 2014 Oct; 62():141-7. PubMed ID: 24907681
[TBL] [Abstract][Full Text] [Related]
40. In situ gelling formulation based on methylcellulose/pectin system for oral-sustained drug delivery to dysphagic patients.
Itoh K; Hatakeyama T; Shimoyama T; Miyazaki S; D'Emanuele A; Attwood D
Drug Dev Ind Pharm; 2011 Jul; 37(7):790-7. PubMed ID: 21405940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
